As a pioneer in the drug transporter field for 15 years, SOLVO is dedicated to exploring the science of transporters and their role in xenobiotic efficacy and safety. With frequent Webinars hosted by respected scholars and professionals, as well as numerous peer-reviewed publications, our commitment and scientific contribution to the transporter field is well recognized. After the great success of the previous events of SOLVO’s Meet the Experts: Transporter Conference series in Budapest and San Francisco we are pleased to announce that the third event will be held in Tokyo on 13 May, 2015. With the Meet the Experts: Transporter Conference series, we took our commitment to the transporter field to a new level. The sessions will focusing on the most relevant and up-to-date aspects of transporter science and industry applications.
Brilliant hosting at Tokyo Marriott Hotel starts with their premier hilltop location in Gotenyama. Inside, dynamic dining venues, polished service, and fingertip technologies keep you as fully engaged as you need to be, throughout your stay. The Gotenyama Garden next to the Tokyo Marriott Hotel is a stroller's oasis right on the premises. History buffs will want to explore the neighborhood's many temples and shrines and other vestiges of Shinagawa's centuries-old role welcoming travelers from afar. If you have any question, please, contact us at email@example.com
You can download the detailed Agenda here!
|Welcome||Péter Krajcsi, SOLVO Biotechnology|
|Methods and Models|
|Keynote: Significance of quantitative targeted absolute proteomics (QTAP)||Tetsuya Terasaki, Tohoku University|
|Development of predictive in vitro models of the proximal tubule for drug development and safety studies||Colin Brown, Newcastle University|
|Integrated approach of in vivo and in vitro evaluation in the risk assessment of transporter-mediated DDI||Noriko Okudaira, Daiichi Sankyo|
|Lunch Seminar: Reagent and service portfolio-Takeshi Sakata, SOLVO Biotechnology|
|Physiology, Pathophysiology, Therapy|
|Keynote: OATP Transporters: Pharmacological and pathophysiological significance||Ikumi Tamai,Kanazawa University|
|Renal urate transporters and hyperuricemia||Naohiko Anzai|
|Bile salt transport - role in hepatotoxicity||Péter Krajcsi, SOLVO Biotechnology|
|Transporters in drug discovery and development|
|Keynote: Transporters-role in pharmacokinetics/pharmacodynamics/toxicodynamics of drugs||Yuichi Sugiyama, Sugiyama Laboratory|
|ABC transporters involved in xenobiotics disposition in the skin||Yukio Kato, Kanazawa University|
|Drug transport studies across the discovery and development phases and beyond; managing potential liabilities against international regulatory expectations||Imad Hanna, Novartis Institutes for BioMedical Research|
|Closing remarks||Péter Krajcsi, SOLVO Biotechnology|
The following speakers are presentig at the conference.
Professor and Chairman Department of Pharmacology and Toxicology Dokkyo Medical University School of Medicine Tochigi, Japan
Dr. Naohiko Anzai is a Full Professor and the chairman of the Department of Pharmacology & Toxicology, Dokkyo Medical University School of Medicine, Tochigi, Japan. He received his Bachelor and Ph.D degrees from Chiba University, Japan. First, he worked at Chiba University Hospital as a Resident, and he started his carrier of basic research at the Department of Physiology, Kitasato University Faculty of Medicine. He engaged to the project of renal tubular potassium transport. He then went to Cote d’Azur, focusing on ASIC channel regulation by protein-protein interaction, at the Institute of Molecular and Cellular Pharmacology, CNRS, France. After this he came back to Japan and joined to the Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo and worked with Professor emeritus Hitoshi Endou and Professor Yoshikatsu Kanai. He extended his research there from ion channels to membrane transporters, particularly that of renal tubular transporters of organic anions, urate, and amino acids. He moved to Dokkyo Medical University School of Medicine, Tochigi, Japan from April 2011. He is a member of the American Physiological Society, American Society of Nephrology, International Society of Nephrology, European Renal Association, and is a Director of the Japanese Society of Digestion and Absorption, an Advisor of the Japanese Society of Hypertension, a Councilor of the Japanese Pharmacological Society, the Physiological Society of Japan, the Japanese Society of Nephrology, and the Japanese Society of Gout and Nucleic Acid Metabolism.
Associate Professor Institute for Cell & Molecular Biosciences, Medical School, Newcastle University Newcastle, UK
Dr Colin Brown was awarded a B.Sc and Ph.D in Physiology and Pharmacology from the University of St Andrews Scotland. He then was a Royal Society European Postdoctoral Research Fellow at the University of Zurich, Switzerland, followed by a Wellcome Trust Senior Fellowship in Biomedical Sciences at the University of Manchester. Until recently, Colin was an Associate Professor at the University of Newcastle where he focussed on developing in vitro models to study drug transport, drug interactions and toxicity in kidney, developing the aProximate in vitro PTC model. In 2018, Dr Brown joined Newcells Biotech as Director of ADMET Technologies.
Senior Fellow Novartis Institutes for BioMedical Research East Hanover, NJ USA
Dr. Imad Hanna is a Group leader in the Department of Drug Metabolism and Pharmacokinetics at Novartis Institutes for BioMedical Research in East Hanover, NJ. Dr. Hanna obtained his B.S. degree in Biochemistry from Oakland University in Rochester, MI. and his Ph.D. in Pharmacology from Wayne State University in Detroit, MI. Following a two-year postdoctoral fellowship at the Center in Molecular Toxicology at Vanderbilt University, Imad joined the Pharmaceutical industry in 2000. Currently, Imad’s group provides drug metabolism and transport support for the registration of clinical drug candidates. Imad is a member of a global team defining scientific/business strategies to assess potential drug interactions with respect to drug transporters. In this regard, he and his colleagues have implemented a number of cell-based drug transport assays in support of this strategy, as well as providing support to ongoing key projects.
Professor Department of Molecular Pharmacotherapeutics Faculty of Pharmacy, Kanazawa University Kanazawa, Japan
Dr. Yukio Kato graduated University of Tokyo in 1990 and received Ph.D.
degree in 1998. He was appointed Research Associate in University of Tokyo in 1993, Visiting Fellow in National Institutes of Health, USA in 2001, Associate Professor in Kanazawa University in 2002, and Full Professor in Kanazawa University in 2008. He was also assigned in 2012 to a Visiting Research Staff in Sugiyama Laboratory, RIKEN.
His major research interests are transporter-mediated drug disposition, efficacy and toxicity, transporter-related inflammation and diseases, and protein-protein interaction and functional regulation of xenobiotic transporters. He published 159 original research articles including 5 Nature journal series papers, and 13 review articles.
Chief Scientific Officer, SOLVO Biotechnology Budaors, Hungary
Dr. Peter Krajcsi has extensive experience in biotechnology. He received his PhD in biochemistry from University of Szeged and later a Doctor of Sciences degree in biological sciences from the Hungarian Academy of Sciences. In his academic career he has focused on three major topics (i) steroid receptors (ii) molecular biology of adenoviruses and (iii) apoptosis. For the past 13 years he has been working in R&D management positions for small and medium size enterprises in drug research and gene therapy in Hungary as well as in the United States. Since 2002 he is the Chief Scientific Officer of Solvo Biotechnology. At Solvo the focus is on membrane transporters and utilization of membrane transporter technology in drug discovery and development as well as in development of diagnostics tools for cancer and inflammatory diseases.
Senior Director Drug Metabolism and Pharmacokinetics Research Laboratories R&D Devision Daiichi Sankyo Co., LTD. Tokyo, Japan
Noriko Okudaira is a senior director in the Drug Metabolism & Pharmacokinetics Research Laboratories of Daiichi Sankyo Co., Ltd. Her current responsibilities are non-clinical ADME studies, PK/PD analysis of small molecules and DDI risk assessment. Her researchinterest is to integrate various in vitro and in vivo data to predict PK, efficacy and toxicity in human using M&S approach. She studied at the University of Tokyo and graduated with a master’s degree in 1985. She obtained Ph.D. degree in pharmaceutical science at the University of Tokyo in 2000. Before joining Daiichi Sankyo, she was employed by Nippon Roche (1985-1991) and Meiji Seika Kaisha (1992-2004).
Head of Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Yokohama, Japan
Yuichi Sugiyama started working as the Head of Sugiyama Laboratory in RIKEN, Yokohama, Japan since 2012. He had been the Professor, Department of Molecular Pharmacokinetics at the University of Tokyo since 1991, retired from the University of Tokyo in 2012 and moved to RIKEN. He has made and continues to make internationally acclaimed contributions to the pharmaceutical sciences in diverse areas. These include physiologically-based pharmacokinetic modelling, the prediction of drug clearance from in vitro data, the quantitative prediction of transporter and enzyme mediated drug-drug interactions based on in vitro studies. His work is internationally recognized by many awards, including AAPS Distinguished Pharmaceutical Scientist Award, 2003, FIP Hoest Madsen Medal in 2009, "Medal with Purple Ribbon" given by Japanese Government in 2010 , B.B.Brodie Award from ASPET in 2012, R.T. Williams Distinguished Scientific Achievement Award (ISSX) in 2013 and Rawls-Palmer Progress in Medicine Award from ASCPT in 2014. He was listed as a top (#1) scientist by ISI in 2007 for the number of citations he received in the preceding 10 years in the field of “Pharmacology and Toxicology”. He served as the chairman of Board of Pharmaceutical Sciences in FIP (2000-2004). He was also the president of both “International society for the study of xenobiotics (ISSX)”.2006-2007).
Professor Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Pharmaceutical Sciences, Kanazawa University Kanazawa, Japan
Education and Professional Experiences;
BS, Kanazawa University 1982, Ph.D; University of Tokyo 1988; Post-doctoral Fellow, University of Chicago and University of Michigan (1989-1991); Professor, Tokyo University of Science (2002-2008); Kanazawa University, Institute of Medical, Pharmaceutical and Health Sciences 2008-present. Head, Venture Business Laboratory, Kanazawa University (2014 – present).
Japanese Society for the Study of Xenobiotics (JSSX); Academy of Pharmaceutical Science and Technology, Japan (APSTJ); Pharmaceutical Society of Japan (PSJ); Japanese Society of Gout and Nucleic Acid Metabolism; American Association of Pharmaceutical Scientists (AAPS); American Society for Pharmacology and Experimental Therapeutics (ASPET); International Society for the Study of Xenobiotics (ISSX).
Board of Committee:
Committee Member of Food Safety Commission, Cabinet Office, Government of Japan (2006 - present); Associate Editor, Biopharmaceutics and Drug Disposition (2009 - present); Editor, Pharmaceutical Research (2017 - present); Councilor, JSSX (2006 – 2013, 2017 - present); Councilor, ISSX (2010 - 2013); Editor in Chief, Drug Metabolism and Pharmacokinetics (DMPK) (2010 - 2013); Associate Editor, Biological Pharmaceutical Bulletin. (2006 - 2008); Editorial Board Member for Journal of Pharmaceutical Sciences, Molecular Pharmaceutics, Pharmaceutical Research and Drug Metabolism and Disposition.
Research of Interest:
Transporters related to Drug-Drug Interaction, Drug-Food Interaction, Drug-induced Toxicity, Regulation of Uric Acid and Prostaglandins, Drug Absorption and Pharmacokinetics.
Distinguished Professor Membrane Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical Sciences, Tohoku University Sendai, Japan
Dr. Tetsuya Terasaki graduated Kanazawa University in 1977 and received Ph.D. degree from University of Tokyo in 1982. He was appointed Full Professor of Tohoku University in 1996 and the University Distinguished Professor of Tohoku University in 2008. He received the Ebert Prize from American Pharmaceutical Association in 1985, the Meritorious Manuscript Award from American Association of Pharmaceutical Scientists in 1996 and 2010, together with three Research Achievement Awards. In April 2013, he received the Medal of Honor with Purple Ribbon, bestowed by the Government of Japan to the most highly honored scientists. His major research interests are the molecular pharmacology of blood-brain barrier function and the pharmacoproteomics. He published extensively in journals, with 309 original research articles and 70 review articles and contributed chapters to over 50 books.